Decision to not accept any proposals for the insulin glargine RFP

Medicines Decision

PHARMAC has decided not accept any proposals for the supply of insulin glargine following consideration of responses to the request for proposals (RFP) for insulin glargine issued on 22 February 2016

This means that there will be no changes to the listing of the current brand of insulin glargine (Lantus) in Section B and Part II of Section H of the Pharmaceutical Schedule as a result of the RFP.

More information

If you have any questions about this decision, you can email us at or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.